{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T07:12:39Z","timestamp":1763017959271,"version":"build-2065373602"},"reference-count":18,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["bbmt.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biology of Blood and Marrow Transplantation"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1016\/j.bbmt.2019.01.007","type":"journal-article","created":{"date-parts":[[2019,1,11]],"date-time":"2019-01-11T09:11:39Z","timestamp":1547197899000},"page":"e169-e173","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Induction Therapy with Bortezomib and Dexamethasone and Conditioning with High-Dose Melphalan and Bortezomib Followed by Autologous Stem Cell Transplantation for Immunoglobulin Light Chain Amyloidosis: Long-Term Follow-Up Analysis"],"prefix":"10.1016","volume":"25","author":[{"given":"Vishal K.","family":"Gupta","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dina","family":"Brauneis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony C.","family":"Shelton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen","family":"Quillen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0075-6735","authenticated-orcid":false,"given":"Shayna","family":"Sarosiek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. Mark","family":"Sloan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6307-2445","authenticated-orcid":false,"given":"Vaishali","family":"Sanchorawala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbmt.2019.01.007_bib0001","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1200\/JCO.2010.30.5235","article-title":"Outcome in renal AL amyloidosis after chemotherapy","volume":"29","author":"Pinney","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2019.01.007_bib0002","doi-asserted-by":"crossref","first-page":"4346","DOI":"10.1182\/blood-2011-01-330738","article-title":"Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients","volume":"118","author":"Cibeira","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2019.01.007_bib0003","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1182\/blood-2007-02-076034","article-title":"Treatment with oral melphalan plus dexamethasone produces long-term remissions in AL amyloidosis","volume":"110","author":"Palladini","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2019.01.007_bib0004","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1182\/blood-2014-04-568329","article-title":"Long-term follow-up from a phase 1\/2 study of single-agent bortezomib in relapsed systemic AL amyloidosis","volume":"124","author":"Reece","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2019.01.007_bib0005","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1182\/blood-2015-01-620302","article-title":"A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis","volume":"126","author":"Palladini","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2019.01.007_bib0006","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1016\/j.bbmt.2015.04.001","article-title":"Induction therapy with bortezomib followed by bortezomib-high dose melphalan and stem cell transplantation for light chain amyloidosis: results of a prospective clinical trial","volume":"21","author":"Sanchorawala","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2019.01.007_bib0007","doi-asserted-by":"crossref","first-page":"4541","DOI":"10.1200\/JCO.2011.37.7614","article-title":"New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes","volume":"30","author":"Palladini","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2019.01.007_bib0008","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1182\/blood-2014-04-570010","article-title":"A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis","volume":"124","author":"Palladini","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2019.01.007_bib0009","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1016\/j.jvir.2015.04.028","article-title":"Nonoperative management of spontaneous splenic rupture in a patient with light-chain amyloidosis: a case report","volume":"26","author":"Bosch","year":"2015","journal-title":"J Vasc Interv Radiol"},{"key":"10.1016\/j.bbmt.2019.01.007_bib0010","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1016\/j.bbmt.2018.07.010","article-title":"Impact of induction therapy on the outcome of immunoglobulin light chain amyloidosis after autologous hematopoietic stem cell transplantation","volume":"24","author":"Afrough","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2019.01.007_bib0011","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1182\/blood-2017-06-788729","article-title":"Hematologic relapse in AL amyloidosis after high-dose melphalan and stem cell transplantation","volume":"130","author":"Browning","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2019.01.007_bib0012","doi-asserted-by":"crossref","first-page":"85","DOI":"10.7326\/0003-4819-140-2-200401200-00008","article-title":"High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study","volume":"140","author":"Skinner","year":"2004","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.bbmt.2019.01.007_bib0013","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/ejh.12282","article-title":"Outcomes and treatments of patients with immunoglobulin light chain amyloidosis who progress or relapse postautologous stem cell transplant","volume":"92","author":"Warsame","year":"2014","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.bbmt.2019.01.007_bib0014","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1002\/ajh.23898","article-title":"Kinetics of organ response and survival following normalization of the serum free light chain ratio in AL amyloidosis","volume":"90","author":"Kaufman","year":"2015","journal-title":"Am J Hematol"},{"key":"10.1016\/j.bbmt.2019.01.007_bib0015","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1741-7015-12-2","article-title":"Induction therapy with bortezomib and dexamethasone followed by autologous stem cell transplantation versus autologous stem cell transplantation alone in the treatment of renal AL amyloidosis: a randomized controlled trial","volume":"12","author":"Huang","year":"2014","journal-title":"BMC Med"},{"key":"10.1016\/j.bbmt.2019.01.007_bib0016","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/leu.2016.229","article-title":"Long-term event-free and overall survival after risk-adapted melphalan and SCT for systemic light chain amyloidosis","volume":"31","author":"Landau","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2019.01.007_bib0017","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/s41408-018-0080-9","article-title":"Immunoglobulin light chain amyloidosis diagnosis and treatment algorithm 2018","volume":"8","author":"Gertz","year":"2018","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.bbmt.2019.01.007_bib0018","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1038\/bmt.2013.192","article-title":"Safety and efficacy of high-dose melphalan and auto-SCT in patients with AL amyloidosis and cardiac involvement","volume":"49","author":"Girnius","year":"2014","journal-title":"Bone Marrow Transplant"}],"container-title":["Biology of Blood and Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879119300151?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879119300151?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T15:05:31Z","timestamp":1761059131000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1083879119300151"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":18,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["S1083879119300151"],"URL":"https:\/\/doi.org\/10.1016\/j.bbmt.2019.01.007","relation":{},"ISSN":["1083-8791"],"issn-type":[{"type":"print","value":"1083-8791"}],"subject":[],"published":{"date-parts":[[2019,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Induction Therapy with Bortezomib and Dexamethasone and Conditioning with High-Dose Melphalan and Bortezomib Followed by Autologous Stem Cell Transplantation for Immunoglobulin Light Chain Amyloidosis: Long-Term Follow-Up Analysis","name":"articletitle","label":"Article Title"},{"value":"Biology of Blood and Marrow Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2019.01.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 American Society for Blood and Marrow Transplantation.","name":"copyright","label":"Copyright"}]}}